Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 2

Interventions

Gemcitabine 154Oxaliplatin 124Fluorouracil 108Capecitabine 105pembrolizumab 93Bevacizumab 79Leucovorin 76Irinotecan 72Nivolumab 70130-nm albumin-bound paclitaxel 68Cisplatin 63Paclitaxel 62Cetuximab 60Cyclophosphamide 48Albumin-Bound Paclitaxel 45Radiotherapy 39Docetaxel 36durvalumab 33Sorafenib 32Taxes 29fludarabine 27Carboplatin 27tislelizumab 25Drug Therapy 25atezolizumab 23Folfox protocol 23regorafenib 20lenvatinib 19Ipilimumab 19sintilimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × TLC 388 × Gastrointestinal × Clear all
NCT03035006 2018-11-06

Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

Taiwan Liposome Company

Phase 1/2 Terminated
1 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01425996 2018-08-21

A Dose-escalation Study of LipotecanĀ® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma

Taiwan Liposome Company

Phase 1/2 Terminated
3 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚔